Dr Arlene Siefker-Radtke - MD Anderson Cancer Centre, Houston, USA
Dr Siefker-Radtke talks to ecancertv at ASCO GU 2015 about the results of a phase II clinical trial of DDMVAC plus bevacizumab and the merits of using basal subtyping to individualise treatment approaches.